Use of agents that silence or inhibit the ATP2B4 gene in promoting uterine contractions
By using agents that silence or inhibit the ATP2B4 gene, calcium ion efflux is regulated, enhancing the contractility of uterine smooth muscle cells. This addresses the issues of lack of high specificity and side effects in existing uterine contraction regulators, achieving more effective uterine contraction control.
Patent Information
- Application Number
- CN202610571459.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-04-28
- Publication Date
- 2026-07-17
AI Technical Summary
Existing uterine contraction regulators lack high specificity in regulating uterine muscle contractions, leading to problems such as abnormal labor and postpartum uterine atony. Furthermore, common drugs have side effects or limited efficacy, and cannot effectively solve problems such as premature birth.
Agents that silence or inhibit the ATP2B4 gene, including nucleic acid molecules, protein molecules, and small molecule compounds, regulate calcium ion efflux, enhance the contractility and frequency of uterine smooth muscle cells, and promote the uterine contraction process.
It effectively enhances the contraction strength and frequency of uterine smooth muscle cells, provides new targets and drug combination strategies, solves problems such as uterine atony and premature birth, and reduces drug side effects.
Smart Images
Figure FT_1 
Figure FT_2 
Figure FT_3